Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Koido, Shigeo ^a   Homma, Sadamu ^a   Okamoto, Masato ^b   Namiki, Yoshihisa ^a   Kan, Shin ^a   Takakura, Kazuki ^a   Kajihara, Mikio ^a   Uchiyama, Kan ^a   Hara, Eiich ^c   Ohkusa, Toshifumi ^a   Gong, Jianlin ^d   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytotoxic T lymphocyte; DC tumor cell fusion vaccine; Dendritic cell; Immunologic tumor cell death; Toll like receptor

Indexed keywords

ALCOHOL; CALRETICULIN; CANCER VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN;

ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CELL FUSION; CELL STIMULATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; IMMUNOGENICITY; IMMUNOSTIMULATION;

EID: 84885754191     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25375     Document Type: Article

References (10)

1. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558-61; PMID:9142127; http://dx.doi.org/10.1038/ nm0597-558
2. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2:e24437; PMID:23762810; http://dx.doi.org/10.4161/onci.24437
3. Koido S, Hara E, Homma S, Namiki Y, Ohkusa T, Gong J, et al. Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol 2009; 2009:657369; PMID:20182533; http://dx.doi. org/10.1155/2009/657369
4. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, et al. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One 2013; 8:e59280; PMID:23555011; http://dx.doi.org/10.1371/journal. pone.0059280
5. Terabe M, Ambrosino E, Takaku S, O'Konek JJ, Venzon D, Lonning S, et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009; 15:6560-9; PMID:19861451; http://dx.doi.org/10.1158/1078- 0432.CCR-09-1066
6. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, et al. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res 2009; 15:6551-9; PMID:19861464; http://dx.doi.org/10.1158/1078- 0432.CCR-09-1067
7. Conroy H, Galvin KC, Higgins SC, Mills KHG. Gene silencing of TGF-ß1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol Immunother 2012; 61:425-31; PMID:22193988; http://dx.doi.org/10.1007/s00262-011-1188-y
8. Zhang M, Berndt BE, Chen JJ, Kao JY. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J Immunol 2008; 181:3690-7; PMID:18714045
9. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, et al. Augmentation of Antitumor Immunity by Fusions of Ethanol-Treated Tumor Cells and Dendritic Cells Stimulated via Dual TLRs through TGF-ß1 Blockade and IL-12p70 Production. PLoS One 2013; 8:e63498; PMID:23717436; http://dx.doi. org/10.1371/journal.pone.0063498
10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252- 64; PMID:22437870; http://dx.doi.org/10.1038/ nrc3239